Amgen Inc (AMGN.OQ)
23 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2013||Chairman of the Board, President, Chief Executive Officer|
|61||2014||Executive Vice President, Chief Financial Officer|
|54||2012||Executive Vice President - Research and Development|
|62||2011||Executive Vice President - Global Commercial Operations|
|60||2013||Executive Vice President - Full Potential Initiatives|
- BRIEF-EU Medicines Agency Recommends Approval Of Amgen Europe, Sandoz Biosimilar Drugs
- BRIEF-Amgen And Allergan Receive Positive CHMP Opinion For Abp 980
- BRIEF-CHMP Recognizes That Amgen's Repatha Prevents Heart Attacks And Strokes
- UPDATE 1-Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
- UPDATE 1-Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam